Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Luiza Martins Nascentes MeloDayana Herrera-RiosDaniel HinzeStefanie LöffekIrem OezelRoberta TurielloJuliane KleinSonia LeonardelliIsa-Vanessa WestedtYahya Al-MatarySara Egea-RodriguezAlexandra BrenzelMaja BauAntje SuckerEva HadaschikFlorian WirsdörferHelmut HanenbergNiklas UhlenbrockDaniel RauhJoanna PoźniakFlorian RambowJean-Christophe MarineMaike EffernNicole GloddeDirk SchadendorfJadwiga JablonskaMichael HudecekIris HelfrichPublished in: Journal for immunotherapy of cancer (2023)
As HSD11B1 inhibitors are in the focus of drug development for metabolic diseases, our data suggest a drug repurposing strategy combining HSD11B1 inhibitors with ICIs to improve melanoma immunotherapy. Furthermore, our work also delineated potential caveats emphasizing the need for careful patient stratification.